Recombinant Human Siglec-9 Protein，His

Siglec-9, or sialic acid-binding immunoglobulin-like lectin 9, is a member of the Siglec family of receptors that play critical roles in regulating immune response, particularly in the context of inflammation and autoimmunity. Research interest in Siglec-9 has surged due to its unique ability to bind sialic acid residues, which are often found on the surface of cells and pathogens. This binding mediates various immune responses, including the inhibition of pro-inflammatory signaling pathways, which can be particularly beneficial in managing chronic inflammatory conditions or in the context of cancer immunotherapy. Moreover, studies have indicated that Siglec-9 is preferentially expressed on myeloid cells, such as macrophages and dendritic cells, suggesting its involvement in modulating immune cell interactions and influencing the adaptive immune response. The recombinant expression of Siglec-9 has enabled researchers to create tools for investigating its functional properties and potential therapeutic applications. Understanding the mechanisms by which Siglec-9 regulates immune responses could pave the way for novel treatments for autoimmune diseases, enhance vaccine efficacy, and improve strategies for cancer immunotherapy. As such, the exploration of Siglec-9 as a therapeutic target is a promising area in immunology, drawing interest from both basic and clinical research fields.